Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
IBS, thyroid cancer drugs approved
FDA OKs two new IBS drugs; EU approves Eisai's thyroid cancer treatment; Gilead's HIV combo, MSD's Hep C drug and BMS's melanoma regimen under review.
Approvals Action
BMS gains new hep C registration
BMS and Norgine have gained new product registrations for hepatititis C and travellers' diarrhoea while Mayne Pharma International has added to the growing list of Alimta competitors.
Working Life
The sales pitch: a matter of questions
Communication is everything for sales reps but how to make it work best? Keep the customer curious says James Wintermann, European area general manager for Astellas.
Pipeline Monitor
EU recommends swag of cancer drugs
Big week for cancer as well as drugs for schizophrenia, cholesterol, COPD, while BMS and Janssen get multiple wins.
Special Report
Your complete PBS reform rundown
The vast PBS reform package released by Health Minister Sussan Ley imposes changes on all parts of the PBS supply chain. Here's your guide to each initiative.